» Articles » PMID: 32155248

Cervical Cancer (over)screening in Belgium and Switzerland: Trends and Social Inequalities

Overview
Specialty Public Health
Date 2020 Mar 11
PMID 32155248
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cervical cancer screening (CCS) by means of Pap smears has led to a decrease in cervical cancer incidence and mortality. In the absence of organized programmes, CCS is opportunistic in Belgium and Switzerland. This might result in a high level of CCS overuse, as screening practices do not conform to the recommended 3-yearly screening interval and the target age-ranges (Belgium: 25-64, Switzerland: 20-70). This study aimed to assess trends in CCS uptake and overuse in Belgium and Switzerland and their social determinants, in the light of reimbursement initiatives, which were implemented in both countries.

Methods: Data from five waves of the Belgian Health Interview Survey (1997-2013) (N=11 141) and Swiss Health Interview Survey (1992-2012) (N=32 696) were used. We performed Poisson regressions to estimate adjusted prevalence ratios (APR), controlled for socio-economic and socio-demographic characteristics and health status. CCS overuse was operationalized as screening more than once every 3 years and screening above recommended age-range.

Results: CCS uptake remained relatively stable over time, with a mean coverage of 70.9% in Belgium and 73.1% in Switzerland. Educational and income gradients were found in both countries. Concerning CCS overuse, women above screening-eligible age showed consistently high screening rates, but screening within the past year declined significantly in both countries, matching the temporal implementation of the reimbursement initiatives.

Conclusions: Although no increase in CCS coverage could be established, CCS has become more efficient in both countries as Pap smear overuse at the population level has declined after the implementation of reimbursement measures tackling CCS overuse.

Citing Articles

Socio-economic inequalities in the use of flu vaccination in Europe: a multilevel approach.

Jemna D, David M, Bonnal L, Oros C Health Econ Rev. 2024; 14(1):61.

PMID: 39083186 PMC: 11292999. DOI: 10.1186/s13561-024-00535-1.


Cervical cancer (over-)screening in Europe: Balancing organised and opportunistic programmes.

De Prez V, Jolidon V, Cullati S, Burton-Jeangros C, Bracke P Scand J Public Health. 2022; 51(8):1239-1247.

PMID: 36016469 PMC: 11796292. DOI: 10.1177/14034948221118215.


Cervical cancer, geographical inequalities, prevention and barriers in resource depleted countries.

Bogdanova A, Andrawos C, Constantinou C Oncol Lett. 2022; 23(4):113.

PMID: 35251344 PMC: 8850967. DOI: 10.3892/ol.2022.13233.


Cervical cancer mortality among young women in Latin America and the Caribbean: trend analysis from 1997 to 2030.

Torres-Roman J, Ronceros-Cardenas L, Valcarcel B, Bazalar-Palacios J, Ybaseta-Medina J, Carioli G BMC Public Health. 2022; 22(1):113.

PMID: 35034604 PMC: 8761303. DOI: 10.1186/s12889-021-12413-0.


Cervical cancer screening programs and their context-dependent effect on inequalities in screening uptake: a dynamic interplay between public health policy and welfare state redistribution.

De Prez V, Jolidon V, Willems B, Cullati S, Burton-Jeangros C, Bracke P Int J Equity Health. 2021; 20(1):211.

PMID: 34560888 PMC: 8464130. DOI: 10.1186/s12939-021-01548-6.